Market: NASD |
Currency: USD
Address: 333 Las Olas Way
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is based in Fort Lauderdale, Florida.
Show more
📈 Sunshine Biopharma, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$7.00
-
Upside/Downside from Analyst Target:
400.00%
-
Broker Call:
2
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
10-25%
-
Upcoming Earnings Date:
-
💰 Dividend History
Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
2024 |
- |
$0.050000 |
- |
2024-08-08 |
- |
Stock split |
$0.010000 |
- |
2024-04-17 |
- |
Stock split |
Total Amount for 2024: $0.060000 |
📅 Earnings & EPS History for Sunshine Biopharma, Inc.
Date | Reported EPS |
---|
2025-08-12 | -0.39 |
2024-11-05 | -0.94 |
2024-08-16 | -198.8 |
2024-05-20 | -40 |
2024-03-28 | -114 |
2023-11-13 | -80 |
2023-08-10 | -40 |
📰 Related News & Research
No related articles found for "sunshine biopharma".